RxDoctor Payments Data

Robert Wayment, MD

Urology · Ogden, UTNPI 1295957280

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (47.4%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 74.5% of it on its own, with 49 other manufacturers making up the rest. Reporting peaked in 2019 at $9,787 and has fallen 79.5% since, to $2,010 in 2025.

$24,957in general payments, 2019–2025

Across 416 payments — averaging $59.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$19K
  • Astellas Pharma US Inc$2K
  • AbbVie$768
  • Dendreon Pharmaceuticals LLC$432
  • Pfizer$425
  • Sumitomo Pharma America, Inc.$334
  • plus $3K from 44 others

What the payments were for

  • Consulting fees$2,45010%
  • Speaking & faculty fees$11,83047%
  • Travel & lodging$5592%
  • Food & beverage$9,56238%
  • Education$5562%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,957 in reported general payments places this provider in the 85th percentile of 96 urology providers in Utah.

See all urology providers in Utah

Medicare billing

Part B allowed, 2024
$276,560
Medicare patients
481
Services billed
6,713

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide156$2,198,748
OrgovyxRelugolix223$587,670
MyrbetriqMirabegron82$58,609
GemtesaVibegron24$19,698
Trospium Chloride ErTrospium Chloride41$9,242
Methenamine Hippurate63$6,045
Tamsulosin Hcl345$6,045
Potassium Citrate ErPotassium Citrate31$3,637
Finasteride284$2,998
Silodosin36$1,538
Trospium Chloride21$1,279
CefuroximeCefuroxime Axetil172$1,246
Solifenacin Succinate45$1,063
Dutasteride11$452
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim45$278

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$1,562$2,257,357238 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$334$607,368247 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 96 urology providers in Utah.

Other urology in Ogden

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →